Development

Interview: Understanding the Attraction for PD-1 Inhibitor Biosimilars

October 13th 2020

By Tony Hagen

Years ahead of patent expirations for programmed death-1 (PD-1) inhibitors, biosimilar companies have begun focusing on these targeted drugs.

PIRG Files Amicus Brief in Support of Humira Plaintiffs

October 13th 2020

By Tony Hagen

Article

The US Public Interest Research Group (PIRG) contends AbbVie's patent thicket for Humira (adalimumab) will encourage anticompetitive practices by other manufacturers.

Celltrion Healthcare Advances Trials for Omalizumab Biosimilar

October 9th 2020

By Tony Hagen

Article

The product would target the lucrative, billion-dollar worldwide market for Xolair.

IQVIA: Biosimilars Could Save $100 Billion Over Next 5 Years

October 6th 2020

By Skylar Jeremias

Article

A report from the IQVIA Institute for Human Data Science states that assessments of the health of the US biosimilar market are too conservative.

Medicure and Reliance Team Up for Cardiovascular Biosimilar

October 6th 2020

By Tony Hagen

Article

The agreement enables Reliance Life Sciences to springboard into the US market using Medicure's commercial reach.

Meier Explains FTC's Power to Pursue Antitrust Activity

September 30th 2020

By Tony Hagen

Article

The Federal Trade Commission's powers to bring antitrust actions are circumscribed by public versus private and what is vs isn't "reasonable," Markus H. Meier explained.

California's Governor Signs Bill for State to Produce Its Own Biosimilars, Insulins

September 29th 2020

By Skylar Jeremias

Article

California has become the first state to implement a policy to produce and distribute its own drug products to help lower costs.

Byvasda Shines in Combination With PD-1 Inhibitor

September 28th 2020

By Skylar Jeremias

Article

Trial results demonstrated that Innovent Biologics’ bevacizumab biosimilar was effective in combination therapy with a PD-1 inhibitor in patients with hepatocellular carcinoma.

Alvotech and DKSH Broaden Their Asia Pipeline Agreement

September 28th 2020

By Skylar Jeremias

Article

A secretive biosimilars company notches yet another co-licensing deal but withholds full details.

Alexion's Ultomiris Gains aHUS Indication in Japan

September 26th 2020

By Tony Hagen

Article

An advance is notched for the ravulizumab (Ultomiris) follow-on product from Alexion. Clinical findings in atypical hemolytic uremic syndrome (aHUS) are provided.